Home Healthcare Medical Devices Novel Drug Delivery System Market

Novel Drug Delivery System Market Size, Share & Trends Analysis Report By Route of Administration (Oral Drug, Injectable Drug, Pulmonary Drug, Transdermal Drug, Others), By Mode of NDSS (Targeted, Controlled, Modulated) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: August 18, 2026 | Author: Jay Mehta | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Novel Drug Delivery System Market, By Route of Administration 2022-2034 (USD MILLION/ Units)
    1. Oral Drug
    2. Injectable Drug
    3. Pulmonary Drug
    4. Transdermal Drug
    5. Others
  2. Novel Drug Delivery System Market, By Mode of NDSS 2022-2034 (USD MILLION/ Units)
    1. Targeted
    2. Controlled
    3. Modulated
  3. Regional Novel Drug Delivery System Market
    1. North America
      1. North America Novel Drug Delivery System Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral Drug
        2. Injectable Drug
        3. Pulmonary Drug
        4. Transdermal Drug
        5. Others
      2. North America Novel Drug Delivery System Market By Mode of NDSS 2022-2034 (USD MILLION/ Units)
        1. Targeted
        2. Controlled
        3. Modulated
      3. U.S.
        1. Oral Drug
        2. Injectable Drug
        3. Pulmonary Drug
        4. Transdermal Drug
        5. Others
        6. Targeted
        7. Controlled
        8. Modulated
      4. Canada
        1. Oral Drug
        2. Injectable Drug
        3. Pulmonary Drug
        4. Transdermal Drug
        5. Others
        6. Targeted
        7. Controlled
        8. Modulated
    2. Europe
      1. Europe Novel Drug Delivery System Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral Drug
        2. Injectable Drug
        3. Pulmonary Drug
        4. Transdermal Drug
        5. Others
      2. Europe Novel Drug Delivery System Market By Mode of NDSS 2022-2034 (USD MILLION/ Units)
        1. Targeted
        2. Controlled
        3. Modulated
      3. U.K.
        1. Oral Drug
        2. Injectable Drug
        3. Pulmonary Drug
        4. Transdermal Drug
        5. Others
        6. Targeted
        7. Controlled
        8. Modulated
      4. Germany
        1. Oral Drug
        2. Injectable Drug
        3. Pulmonary Drug
        4. Transdermal Drug
        5. Others
        6. Targeted
        7. Controlled
        8. Modulated
      5. France
        1. Oral Drug
        2. Injectable Drug
        3. Pulmonary Drug
        4. Transdermal Drug
        5. Others
        6. Targeted
        7. Controlled
        8. Modulated
      6. Spain
        1. Oral Drug
        2. Injectable Drug
        3. Pulmonary Drug
        4. Transdermal Drug
        5. Others
        6. Targeted
        7. Controlled
        8. Modulated
      7. Italy
        1. Oral Drug
        2. Injectable Drug
        3. Pulmonary Drug
        4. Transdermal Drug
        5. Others
        6. Targeted
        7. Controlled
        8. Modulated
      8. Russia
        1. Oral Drug
        2. Injectable Drug
        3. Pulmonary Drug
        4. Transdermal Drug
        5. Others
        6. Targeted
        7. Controlled
        8. Modulated
      9. Nordic
        1. Oral Drug
        2. Injectable Drug
        3. Pulmonary Drug
        4. Transdermal Drug
        5. Others
        6. Targeted
        7. Controlled
        8. Modulated
      10. Benelux
        1. Oral Drug
        2. Injectable Drug
        3. Pulmonary Drug
        4. Transdermal Drug
        5. Others
        6. Targeted
        7. Controlled
        8. Modulated
      11. Rest of Europe
        1. Oral Drug
        2. Injectable Drug
        3. Pulmonary Drug
        4. Transdermal Drug
        5. Others
        6. Targeted
        7. Controlled
        8. Modulated
    3. APAC
      1. APAC Novel Drug Delivery System Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral Drug
        2. Injectable Drug
        3. Pulmonary Drug
        4. Transdermal Drug
        5. Others
      2. APAC Novel Drug Delivery System Market By Mode of NDSS 2022-2034 (USD MILLION/ Units)
        1. Targeted
        2. Controlled
        3. Modulated
      3. China
        1. Oral Drug
        2. Injectable Drug
        3. Pulmonary Drug
        4. Transdermal Drug
        5. Others
        6. Targeted
        7. Controlled
        8. Modulated
      4. Korea
        1. Oral Drug
        2. Injectable Drug
        3. Pulmonary Drug
        4. Transdermal Drug
        5. Others
        6. Targeted
        7. Controlled
        8. Modulated
      5. Japan
        1. Oral Drug
        2. Injectable Drug
        3. Pulmonary Drug
        4. Transdermal Drug
        5. Others
        6. Targeted
        7. Controlled
        8. Modulated
      6. India
        1. Oral Drug
        2. Injectable Drug
        3. Pulmonary Drug
        4. Transdermal Drug
        5. Others
        6. Targeted
        7. Controlled
        8. Modulated
      7. Australia
        1. Oral Drug
        2. Injectable Drug
        3. Pulmonary Drug
        4. Transdermal Drug
        5. Others
        6. Targeted
        7. Controlled
        8. Modulated
      8. Taiwan
        1. Oral Drug
        2. Injectable Drug
        3. Pulmonary Drug
        4. Transdermal Drug
        5. Others
        6. Targeted
        7. Controlled
        8. Modulated
      9. South East Asia
        1. Oral Drug
        2. Injectable Drug
        3. Pulmonary Drug
        4. Transdermal Drug
        5. Others
        6. Targeted
        7. Controlled
        8. Modulated
      10. Rest of Asia-Pacific
        1. Oral Drug
        2. Injectable Drug
        3. Pulmonary Drug
        4. Transdermal Drug
        5. Others
        6. Targeted
        7. Controlled
        8. Modulated
    4. Middle East and Africa
      1. Middle East and Africa Novel Drug Delivery System Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral Drug
        2. Injectable Drug
        3. Pulmonary Drug
        4. Transdermal Drug
        5. Others
      2. Middle East and Africa Novel Drug Delivery System Market By Mode of NDSS 2022-2034 (USD MILLION/ Units)
        1. Targeted
        2. Controlled
        3. Modulated
      3. UAE
        1. Oral Drug
        2. Injectable Drug
        3. Pulmonary Drug
        4. Transdermal Drug
        5. Others
        6. Targeted
        7. Controlled
        8. Modulated
      4. Turkey
        1. Oral Drug
        2. Injectable Drug
        3. Pulmonary Drug
        4. Transdermal Drug
        5. Others
        6. Targeted
        7. Controlled
        8. Modulated
      5. Saudi Arabia
        1. Oral Drug
        2. Injectable Drug
        3. Pulmonary Drug
        4. Transdermal Drug
        5. Others
        6. Targeted
        7. Controlled
        8. Modulated
      6. South Africa
        1. Oral Drug
        2. Injectable Drug
        3. Pulmonary Drug
        4. Transdermal Drug
        5. Others
        6. Targeted
        7. Controlled
        8. Modulated
      7. Egypt
        1. Oral Drug
        2. Injectable Drug
        3. Pulmonary Drug
        4. Transdermal Drug
        5. Others
        6. Targeted
        7. Controlled
        8. Modulated
      8. Nigeria
        1. Oral Drug
        2. Injectable Drug
        3. Pulmonary Drug
        4. Transdermal Drug
        5. Others
        6. Targeted
        7. Controlled
        8. Modulated
      9. Rest of MEA
        1. Oral Drug
        2. Injectable Drug
        3. Pulmonary Drug
        4. Transdermal Drug
        5. Others
        6. Targeted
        7. Controlled
        8. Modulated
    5. LATAM
      1. LATAM Novel Drug Delivery System Market By Route of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral Drug
        2. Injectable Drug
        3. Pulmonary Drug
        4. Transdermal Drug
        5. Others
      2. LATAM Novel Drug Delivery System Market By Mode of NDSS 2022-2034 (USD MILLION/ Units)
        1. Targeted
        2. Controlled
        3. Modulated
      3. Brazil
        1. Oral Drug
        2. Injectable Drug
        3. Pulmonary Drug
        4. Transdermal Drug
        5. Others
        6. Targeted
        7. Controlled
        8. Modulated
      4. Mexico
        1. Oral Drug
        2. Injectable Drug
        3. Pulmonary Drug
        4. Transdermal Drug
        5. Others
        6. Targeted
        7. Controlled
        8. Modulated
      5. Argentina
        1. Oral Drug
        2. Injectable Drug
        3. Pulmonary Drug
        4. Transdermal Drug
        5. Others
        6. Targeted
        7. Controlled
        8. Modulated
      6. Chile
        1. Oral Drug
        2. Injectable Drug
        3. Pulmonary Drug
        4. Transdermal Drug
        5. Others
        6. Targeted
        7. Controlled
        8. Modulated
      7. Colombia
        1. Oral Drug
        2. Injectable Drug
        3. Pulmonary Drug
        4. Transdermal Drug
        5. Others
        6. Targeted
        7. Controlled
        8. Modulated
      8. Rest of LATAM
        1. Oral Drug
        2. Injectable Drug
        3. Pulmonary Drug
        4. Transdermal Drug
        5. Others
        6. Targeted
        7. Controlled
        8. Modulated
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.